Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Casparov Jul. 29 at 10:42 AM

$IOBT Mai-Britt Zocca (CEO): “We are actively building relationships with key opinion leaders and potential commercial partners to facilitate a smooth market introduction. The differentiation of Cylembio®, based on the unique T-cell targeting, is a strong point in discussions with payers and regulatory authorities.”

0 · Reply

Casparov Jul. 29 at 10:41 AM

$IOBT Mai-Britt Zocca (CEO): “We expect the primary endpoint readout of our Phase III study with Cylembio® and pembrolizumab in Q3 this year. The interim data so far are encouraging and confirm our hypothesis that this combination significantly enhances the anti-tumor immune response. We are preparing for a smooth transition to regulatory filing once we have positive results.”

0 · Reply

MakeBux Jul. 29 at 9:48 AM

$IOBT is at a 2+ year high- a very bullish sign. $IOBT closed in the upper quadrant of yesterdays spike, also a very bullish sign. This is definitely one to watch.

0 · Reply

algo_alpha Jul. 29 at 3:07 AM

Then: 📞 You called the floor. 📣 You didn’t wait — you acted. 🧠 Every trade carried weight because you had to own it. Now: 📱 You wait for green. 💬 You check what everyone else thinks. 🎯 It’s less about conviction, more about confirmation. 📉 You Wake Up as a Trader on Wall Street, 1986… When hesitation cost more than being wrong. https://www.youtube.com/watch?v=pRl2wYnIHTo $INTC $IOBT $IOVA $IREN $JASMY.X

1 · Reply

DrUpUpAway Jul. 29 at 3:05 AM

$IOBT Lots of chatter now, retail mostly even with 2mil trading today, the bigger boys are still not come. I've shown the volume void in this zone, the warrants are here. Break out sustained to $3's+ would be nice but a new price floor here is also important. But be ready for the out of blue premarket data release and auto reprice. Negative $0.50 Positive $8-10? $14 ipo? $20?!! Mads amino sequences for the win!. iykyk ha!

1 · Reply

justiceforb_85 Jul. 29 at 2:49 AM

$IOBT continues to show strength. Even with the recent increase in stock price, this market cap is ridiculously low if their phase 3 trial is positive.

0 · Reply

algo_alpha Jul. 29 at 1:57 AM

Then: 📞 No alerts. No notifications. 📣 You were the market scanner. Now: 📱 $INTC buzz on FinTwit. 🧠 $IOBT sentiment bots. 📊 You need five indicators to press “Buy.” 📉 You Wake Up as a Trader on Wall Street, 1986… No screen time. Just floor time. 🎧 https://www.youtube.com/watch?v=pRl2wYnIHTo $INTC $IOBT $IOVA $IREN $JASMY.X

0 · Reply

algo_alpha Jul. 29 at 1:06 AM

Imagine shouting your order over a hundred other voices. No mouse. No charts. Just nerve. 📉 You Wake Up as a Trader on Wall Street, 1986… Built for market junkies. Dreamed for degens. 🎧 https://www.youtube.com/watch?v=pRl2wYnIHTo $IOBT $IOVA $IREN $LIDR $MCVT

0 · Reply

MakeBux Jul. 28 at 10:33 PM

$IOBT This stock has legs. It's been in an uptrend since November of last year, and now it's accelerating upwards. This was a big move today. I expect to see many more in the upcoming days/weeks.

0 · Reply

NVDAMillionaire Jul. 28 at 8:08 PM

$IOBT Excellent article that nails exactly where IOBT stands right now. So if you want to update your IOBT knowledge or get acquainted with IOBT, this is a must read. https://beyondspx.com/article/io-biotech-a-high-stakes-bet-on-t-win-technology-ahead-of-pivotal-melanoma-data-iobt

0 · Reply

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 2 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 3 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 3 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 4 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 4 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 5 months ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 5 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 5 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 6 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 7 months ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 7 months ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 9 months ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 11, 2024, 4:05 PM EST - 9 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2024, 10:00 AM EST - 9 months ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 10 months ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 11 months ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 11 months ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 1 year ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 1 year ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 1 year ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 1 year ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 1 year ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 1 year ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 1 year ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 1 year ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 12, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Aug 11, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 8, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

Aug 7, 2023, 8:30 AM EDT - 2 years ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Jul 28, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

Jul 25, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

Jul 18, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

Jun 14, 2023, 8:00 AM EDT - 2 years ago

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

Jun 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

May 30, 2023, 4:35 PM EDT - 2 years ago

IO Biotech to Present at the Jefferies Healthcare Conference

May 11, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Announces 2023 First-Quarter Results

Mar 14, 2023, 4:11 PM EDT - 2 years ago

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

Casparov Jul. 29 at 10:42 AM

0 · Reply

Casparov Jul. 29 at 10:41 AM

0 · Reply

MakeBux Jul. 29 at 9:48 AM

$IOBT is at a 2+ year high- a very bullish sign. $IOBT closed in the upper quadrant of yesterdays spike, also a very bullish sign. This is definitely one to watch.

0 · Reply

algo_alpha Jul. 29 at 3:07 AM

1 · Reply

DrUpUpAway Jul. 29 at 3:05 AM

1 · Reply

justiceforb_85 Jul. 29 at 2:49 AM

$IOBT continues to show strength. Even with the recent increase in stock price, this market cap is ridiculously low if their phase 3 trial is positive.

0 · Reply

algo_alpha Jul. 29 at 1:57 AM

0 · Reply

algo_alpha Jul. 29 at 1:06 AM

0 · Reply

MakeBux Jul. 28 at 10:33 PM

$IOBT This stock has legs. It's been in an uptrend since November of last year, and now it's accelerating upwards. This was a big move today. I expect to see many more in the upcoming days/weeks.

0 · Reply

NVDAMillionaire Jul. 28 at 8:08 PM

0 · Reply

Doozio Jul. 28 at 7:20 PM

$IOBT maybe let’s scrabble bag it $RBOT wen all da furu 🐑 been SPOT. 🐒🍌🧠⏰♾️

1 · Reply

badprecog Jul. 28 at 6:17 PM

$IOBT n=17 is small but in CheckMate-067 PD-L1+ ORR came in at 58.9%. Seems like a lock for best in class but seems like a ring the bell before the fight begins for PD-L1+!

0 · Reply